Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

[This corrects the article on p. 213 in vol. 4, PMID: 29238708.].

In the original article, there was a mistake in Figure 1 as published [x and y axes were mislabeled and ⋆p-value <0.05 indicating significance was missing]. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Figure 1

Changes in %forced vital capacity (ΔFVC) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.

In the original article, there was a mistake in Figure 2 as published [x and y axes were mislabeled and ⋆p-value <0.05 indicating significance was missing]. The corrected Figure 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Figure 2

Changes in %diffusion capacity of lung for carbon monoxide (ΔDLCO) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.

The original article was updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.